<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/abel/Downloads/grobid-0.5.6/grobid-home/schemas/xsd/Grobid.xsd" xml:space="preserve">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" />
			</titleStmt>
			<publicationStmt>
				<publisher />
				<availability status="unknown"><licence /></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<affiliation key="aff0">
								<orgName key="dep1" type="department">Lindsley F. Kimball Research Institute</orgName>
								<orgName key="dep2" type="department">Institute of Microbiology and Epidemiology</orgName>
								<orgName type="laboratory">State Key Laboratory of Pathogen and Biosecurity</orgName>
								<orgName type="institution">New York Blood Center</orgName>
								<address>
									<addrLine>310 East 67th Street</addrLine>
									<postCode>10065, 100071</postCode>
									<settlement>Beijing, Beijing</settlement>
									<region>New York, New York</region>
									<country>USA, China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName key="dep1" type="department">School of Pharmaceutical Sciences</orgName>
								<orgName key="dep2" type="department">|| Department of Microbiology</orgName>
								<orgName type="institution">Southern Medical University</orgName>
								<address>
									<postCode>510515</postCode>
									<settlement>Guangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">University of Hong Kong</orgName>
								<address>
									<addrLine>Pokfulam, Hong Kong SAR</addrLine>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
					</analytic>
					<monogr>
						<imprint>
							<date />
						</imprint>
					</monogr>
					<idno type="DOI">10.1038/nrmicro2090</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>

		<encodingDesc>
			<appInfo>
				<application ident="GROBID" version="0.5.6" when="2020-03-16T22:29+0000">
					<ref target="https://github.com/kermitt2/grobid">GROBID - A machine learning software for extracting information from scholarly documents</ref>
				</application>
			</appInfo>
		</encodingDesc>		<profileDesc>
			<abstract />
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div> <p>. The most recent epidemic of SARS occurred in Beijing and Anhui in China in April 2004 and originated from laboratory contamination (WHO update 7; see Further information). Since then, no new case of SARS has been reported, possibly because of continued global vigilance and surveillance and laboratory bio-safety practices, as well as the euthanizing or quarantining of animals that may have been exposed to SARS-CoV </p><p>Infection with SARS-CoV can trigger a series of humoral and cellular immune responses. Specific antibodies against SARS-CoV (immunoglobulin G (IgG) and IgM) were detectable approximately 2 weeks postinfection, reaching a peak 60 days post-infection and remaining at high levels until 180 days post-infection </p></div>
<div><head>Adaptive evolution</head><p>A process that enables living organisms to cope with environmental stresses and pressures for survival in a new host. for example, under positive selective pressure, civet SArS-CoV can evolve and subsequently adapt to the human host.</p><p>Neutralizing antibodies and/or T-cell immune responses can be raised directly against several SARS-CoV proteins </p></div>
<div><head>Structure of the SARS-CoV S protein</head><p>The spikes of SARS-CoV are composed of trimers of S protein, which belongs to a group of class I viral fusion glycoproteins that also includes HIV glycoprotein 160 (Env), influenza haemagglutinin (HA), paramyxovirus F and Ebola virus glycoprotein </p><p>Angiotensin-converting enzyme 2 (ACE2) has been identified as the receptor of SARS-CoV </p><p>Human and animal SARS-CoVs depend on ACE2 for cell entry. Animal SARS-CoV could evolve to infect humans by a series of transmission events between animals and humans. For example, a chimeric recombinant SARS-CoV that bears the S protein of civet SARS-CoV (icSZ16-S) can adapt to human airway epithelial cells and displays enhanced affinity for human ACE2 (ref. </p><p>Functions of the SARS-CoV S protein SARS-CoV S protein has pivotal roles in viral infection and pathogenesis </p><p>Receptor binding. The RBD in S1 is responsible for virus binding to host cell receptors </p></div>
<div><head>Box 1 | Pathology of SARS and the life cycle of SARS-CoV infection</head><p>Severe acute respiratory syndrome-coronavirus (SARS-CoV) spreads primarily through droplets (respiratory secretions) and close person-to-person contact. After the virus enters into the body, it binds to primary target cells that express abundant virus receptor, the angiotensin-converting enzyme 2 (ACE2), including pneumocytes and enterocytes in the respiratory system. The virus enters and replicates in these cells. The matured virions are then released to infect new target cells </p></div>
<div><head>Nature Reviews | Microbiology</head></div>
<div><head>Viral fusion.</head><p>The fusion process that is mediated by S protein of SARS-CoV is similar to that mediated by class I viral fusion proteins of other viruses, such as HIV-1 and murine hepatitis virus (MHV) </p></div>
<div><head>Nature Reviews | Microbiology</head></div>
<div><head>SARS pseudovirus</head><p>A synthetic virus that bears the SArS-CoV S protein and contains an env-defective, luciferase-expressing genome of a retrovirus (for example, HiV), and can infect but does not replicate in cells that express receptors for SArS-CoV. and HR2 domains to form a six-helix bundle fusion core structure. This brings the viral envelope and target cell membrane into close proximity for fusion. The crystal structure of the SARS-CoV fusion core is described in detail in ref. </p><p>Vaccines based on the SARS-CoV S protein The roles of S protein in receptor binding and membrane fusion indicate that vaccines based on the S protein could induce antibodies to block virus binding and fusion or neutralize virus infection. Among all structural proteins of SARS-CoV, S protein is the main antigenic component that is responsible for inducing host immune responses, neutralizing antibodies and/or protective immunity against virus infection. S protein has therefore been selected as an important target for vaccine and antiviral development. A comparison of these approaches is provided in </p></div>
<div><head>Vaccines based on the full-length S protein.</head><p>Several vaccines that are based on the full-length S protein of SARS-CoV have been reported. Yang et al. </p><p>Although full-length S protein-based SARS vaccines can induce neutralizing antibody responses against SARS-CoV infection, they may also induce harmful immune responses that cause liver damage of the vaccinated animals or enhanced infection after challenge with b | Crystal structures of the RBD complexed with the receptor. RBD (the core structure is cyan and the loop RBM is red) interacts with the receptor angiotensin-converting enzyme 2 (ACE2; green). A five-stranded anti-parallel &#946;-sheet (&#946;1-&#946;4 and &#946;7) that connects with three short &#945;-helices (&#945;A-&#945;C) constitutes the core, whereas a two-stranded &#946;-sheet (&#946;5 and &#946;6) forms the loop. N* and C* represent the amino and carboxyl termini of the RBD, respectively. c | The RBD tyrosine (magenta) and cysteine (yellow) residue distribution </p></div>
<div><head>Vaccines based on the RBD. Previous studies have</head><p>shown that the RBDs of the S proteins of the coronaviruses MHV and HCoV-229E contain major antigenic determinants that can induce neutralizing antibodies </p><p>We have discovered that the recombinant RBD (rRBD) antigen of SARS-CoV is highly reactive with the neutralizing antibodies against SARS pseudoviruses that bear S proteins of SARS-CoV (Tor2 strain) in the antisera of mice and rabbits immunized with inactivated SARS-CoV </p></div>
<div><head>S protein-based therapeutics Peptides that interrupt the RBD-ACE2 interaction.</head><p>It has been shown that rRBD blocks S protein-mediated entry of lentivirus pseudotypes into ACE2-expressing 293T cells with a half maximal inhibitory concentration (IC 50 ) of less than 10 nM 30 . Similarly, a peptide that overlaps the RBD sequence (amino acids 471-503) blocks the RBD-ACE2 interaction, inhibiting SARS-CoV entry into Vero cells with an IC 50 of approximately 40 &#956;M 82 . A polypeptide that contains two RBD-binding motifs of ACE2 (amino acids 22-44 and 351-357) linked by a glycine exhibits high potent inhibitory activity on SARS pseudovirus infection in ACE2-expressing HeLa cells with an IC 50 of 100 nM 83 . These findings suggest that peptides derived from both RBD and ACE2 that block RBD-ACE2 binding could be developed as novel therapeutics against SARS-CoV infection. However, the in vivo inhibitory activity of these peptides should be evaluated in animal models before considering further development.</p></div>
<div><head>Peptides that interfere with the cleavage of S protein.</head><p>Cleavage of the S protein trimer is an important event in infection, making the potential cleavage site between S1 and S2 domains another target for development of anti-SARS-CoV agents. Synthetic peptides, including P6 (amino acids 598-617) and P8 (amino acids 737-756), both of which are close to the S1-S2 connection and cleavage site, exhibit potent inhibitory activity against the GZ50 strain of SARS-CoV infection in fetal rhesus kidney  </p></div>
<div><head>Peptides that block the HR1-HR2 interaction from forming a fusion-active core.</head><p>In the early 1990s, Jiang et al. </p><p>One of the disadvantages of using HR2-based peptide inhibitors is the potential selection of escape mutants with altered host-range phenotypes </p><p>mAbs that target the S protein Neutralizing mouse mAbs. using rRBD and inactivated SARS-CoV as immunogens, we have successfully generated a panel of highly potent neutralizing mouse monoclonal antibodies (mAbs) that could block receptor binding and cross-neutralize infection by pseudoviruses that bore S proteins of the representative human SARS </p></div>
<div><head>Other compounds and small molecules that target the S protein.</head><p>Several other compounds and small molecules that target the S protein have been reported. For example, amiodarone blocks the in vitro spread of SARS-CoV by inhibiting virus infection at a postendosomal level </p><p>Gene targeting with small interfering RNA. RNA interference induced by a small interfering RNA (siRNA) has been successfully used recently as a specific and efficient method for silencing specific viral genes, interrupting protein synthesis and suppressing virus replication </p></div>
<div><head>Conclusions and prospects</head><p>In summary, the S protein of SARS-CoV possesses some unique features that are different from other type I glycoproteins. Many class I fusion proteins, such as HIV Env, influenza HA and MHV S, are posttranslationally cleaved at the N-proximal region of the fusion peptide by specific proteases into the surface and transmembrane subunits. By contrast, cleavage of the SARS-CoV S protein may occur far upstream of the predicted fusion peptide </p><p>The interaction between the SARS-CoV S protein and ACE2 is essential for SARS-CoV entry. The natural evolution of the epidemic SARS-CoV strains probably occurred over a long period, through the repeated transmission of viruses from animals to humans and from humans to animals, resulting in mutations in both the SARS-CoV S protein and ACE2, so that human and animal SARS-CoVs could enter cells that bore human or animal ACE2. Further understanding of the tropism of the virus and the mechanism of the SARS-CoV S protein in receptor binding and entry is therefore important for the development of anti-SARS-CoV therapeutics and vaccines.</p><p>As the major component for the development of vaccines against SARS, S protein, and especially the RBD, has been shown to induce highly potent neutralizing antibodies to block virus binding and membrane fusion and/or protective immunity against virus infection. Owing to the absence of human SARS cases in recent years, future SARS epidemics will probably originate from zoonotic transmission. SARS vaccines should therefore protect against not only human SARS-CoV strains, including those from early, middle and late phases of the epidemic, but also those of zoonotic origin. Although current vaccine candidates effectively neutralize SARS-CoV in young-animal replication models without clinical symptoms, they may not protect an elderly population against SARS-CoV infection. Thus, it is essential to test the vaccine candidates in robust lethal-challenge models using aged animals. Future vaccines should effectively protect both the young and the elderly populations from infection by either human or animal SARS-CoV strains that may cause future SARS epidemics.</p><p>Peptides and non-peptidic small molecules that target the functional domain of the SARS-CoV S protein, particularly the RBD in the S1 subunit and the HR2 region in the S2 subunit, are mainly virus entry inhibitors and can be further developed as anti-SARS-CoV therapeutics. To develop these molecules as effective and safe antiviral drugs for the treatment of SARS, the urgent task is to improve their potency. Mouse and human mAbs that target the S protein of SARS-CoV have shown potent inhibition and/or neutralization to homologous and heterologous SARS-CoV isolates and can be further developed as immunotherapeutics or passive immunization agents for therapy and prophylaxis of SARS-CoV infection. Future studies are needed to test the in vivo efficacy of these antiviral agents in animal models.</p><p>Overall, the feasibility of using peptides and small molecules as anti-SARS therapeutics is partially limited by their low antiviral potency. Furthermore, the possibility of enhancing viral entry might restrict mAbs as immunotherapeutics for long-term use. It is likely, however, that S protein-based vaccines will bear fruit in the near future, as they have been proven to induce long-term and potent neutralizing antibodies and/or protective immunity against SARS-CoV. But the in vivo efficacy of these vaccine candidates in elderly and lethal-challenge models, and their protection against zoonotic virus infection, should be determined before a clinical study is initiated. To take these factors into full consideration, a combination of different strategies with multiple vaccines and antiviral therapeutics may be needed to induce broad and cross protection against various virus strains, especially isolates that have mutated quickly. Early clinical studies that were based on such strategies have been carried out, but it is difficult to push the clinical trials of these candidate vaccines and therapeutics forwards owing to a lack of SARS-CoV-infected subjects and insufficient financial support. Thus, most big pharmaceutical companies have no interest in developing SARS vaccines and therapeutics because of the concern of profitability. However, studies on SARS will provide important information for designing novel strategies for prophylaxis and therapies of other newly emerging infections caused by enveloped viruses with class I fusion proteins.</p></div><note place="foot">&#169; 2009 Macmillan Publishers Limited. All rights reserved</note>
			<note place="foot">www.nature.com/reviews/micro &#169; 2009 Macmillan Publishers Limited. All rights reserved</note>
			<note place="foot">&#169; 2009 Macmillan Publishers Limited. All rights reserved Nature Reviews | Microbiology</note>
		<figDesc>outbreak of SARS was brought under control in July 2003 by effective quarantine, patient-isolation and travel restrictions. Four sporadic SARS cases caused by different SARS-CoV isolates than those that predominated in the 2002-2003 outbreak were reported in late 2003 and early 2004 (refS</figDesc><figDesc>The life cycle of SArS-coV in host cells. Severe acute respiratory syndrome-coronavirus (SARS-CoV) enters target cells through an endosomal pathway</figDesc><figDesc>SArS-coV S protein structure and its complex with the receptor AcE2. a | Schematic of the S protein</figDesc><figDesc>CP, cytoplasm domain; FP, fusion peptide; HR, heptad repeat; RBD, receptor-binding domain; RBM, receptor-binding motif; SP, signal peptide; TM, transmembrane domain. Parts b and c are adapted, with permission, from ref. 29 &#63193; (2005) American Association for the Advancement of Science. SARS-CoV 64,65 , raising concerns about the safety and ultimate protective efficacy of vaccines that contain the full-length SARS-CoV S protein.</figDesc><figDesc /><figDesc>The fusion core structure. The fusion core is a six-helix bundle with three HR2 &#945;-helices packed in an oblique antiparallel manner against the hydrophobic grooves on the surface of the central HR1 trimer</figDesc><figDesc>S protein-based vaccines and antiviral therapies against SARS-CoVInhibits virus entry, neutralizes virus infection, induces cross protection and reduces disease severity and viral burden; more suitable to development as human immunotherapeutics</figDesc></body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgements</head><p>We thank all three anonymous reviewers for their constructive comments and informative suggestions. </p></div>
			</div>

			<div type="annex">
<div><p>The earliest demonstration that the RBD of SARS-CoV S protein induces highly potent neutralizing antibodies against SARS-CoV infection. </p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Zhong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope from="1353" to="1358" unit="page" />
			<date type="published" when="2003-02" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kuiken</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope from="263" to="270" unit="page" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The genome sequence of the SARSassociated coronavirus</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Marra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">300</biblScope>
			<biblScope from="1399" to="1404" unit="page" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Coronavirus as a possible cause of severe acute respiratory syndrome</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Peiris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope from="1319" to="1325" unit="page" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Characterization of a novel coronavirus associated with severe acute respiratory syndrome</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Rota</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">300</biblScope>
			<biblScope from="1394" to="1399" unit="page" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
	<note>Together with References 3 and 4, this article provided one of the earliest views of the SARS-CoV genome</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Guan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">302</biblScope>
			<biblScope from="276" to="278" unit="page" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
	<note>First demonstration of SARS-CoV animal transmission</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Bats are natural reservoirs of SARS-like coronaviruses</title>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope from="676" to="679" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Lau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope from="14040" to="14045" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Severe acute respiratory syndrome (SARS): a year in review</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Skowronski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu. Rev. Med</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope from="357" to="381" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003-2004 community outbreak of SARS in Guangzhou</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Che</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">China. Clin. Infect. Dis</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope from="1" to="5" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">SARS virus returns to China as scientists race to find effective vaccine</title>
		<author>
			<persName><forename type="first">F</forename><surname>Fleck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bull. World Health Organ</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope from="152" to="153" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Laboratory diagnosis of four recent sporadic cases of community-acquired SARS</title>
		<author>
			<persName><forename type="first">G</forename><surname>Liang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">China. Emerg. Infect. Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope from="1774" to="1781" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A review of studies on animal reservoirs of the SARS coronavirus</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Hu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virus Res</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope from="74" to="87" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Severe acute respiratory syndrome -retrospect and lessons of 2004 outbreak in China</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">N</forename><surname>Liang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed. Environ. Sci</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope from="445" to="451" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Infectious diseases. Mounting lab accidents raise SARS fears</title>
		<author>
			<persName><forename type="first">D</forename><surname>Normile</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">304</biblScope>
			<biblScope from="659" to="661" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Laboratory-acquired SARS raises worries on biosafety</title>
		<author>
			<persName><forename type="first">C</forename><surname>Orellana</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect. Dis</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">64</biblScope>
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Evaluation by indirect immunofluorescent assay and enzyme linked immunosorbent assay of the dynamic changes of serum antibody responses against severe acute respiratory syndrome coronavirus</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Mo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin. Med. J</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope from="446" to="450" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Immunological responses against SARS-coronavirus infection in humans</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Gao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell. Mol. Immunol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope from="119" to="122" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope from="3401" to="3408" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus</title>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">24</biblScope>
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>See</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Gen. Virol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope from="2136" to="2146" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Dutta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol. Lett</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope from="65" to="71" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice</title>
		<author>
			<persName><forename type="first">H</forename><surname>Jin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">328</biblScope>
			<biblScope from="979" to="986" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virology</title>
		<imprint>
			<biblScope unit="volume">335</biblScope>
			<biblScope from="34" to="45" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">J</forename><surname>Buchholz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope from="9804" to="9809" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Zakhartchouk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope from="136" to="143" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groups</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>He</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Microbiol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">88</biblScope>
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Structural basis for membrane fusion by enveloped viruses</title>
		<author>
			<persName><forename type="first">W</forename><surname>Weissenhorn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Membr. Biol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope from="3" to="9" unit="page" />
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Structure of SARS coronavirus spike receptor-binding domain complexed with receptor</title>
		<author>
			<persName><forename type="first">F</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Farzan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Harrison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">309</biblScope>
			<biblScope from="1864" to="1868" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensinconverting enzyme 2</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Choe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Farzan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">279</biblScope>
			<biblScope from="3197" to="3201" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein</title>
		<author>
			<persName><forename type="first">B</forename><surname>Sainz</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rausch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Gallaher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Garry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Wimley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope from="7195" to="7206" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope from="5900" to="5906" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain</title>
		<author>
			<persName><forename type="first">F</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope from="6794" to="6800" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity</title>
		<author>
			<persName><forename type="first">L</forename><surname>Du</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope from="174" to="179" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Cathepsin L functionally cleaves the SARS-CoV class I fusion protein upstream of rather than adjacent to the fusion peptide</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Bartelink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Rottier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope from="8887" to="8890" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase</title>
		<author>
			<persName><forename type="first">L</forename><surname>Lai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr. Pharm. Des</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope from="4555" to="4564" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</title>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">First demonstration that ACE2 is a functional receptor of SARS-CoV</title>
		<imprint>
			<date type="published" when="2003" />
			<biblScope unit="volume">426</biblScope>
			<biblScope from="450" to="454" unit="page" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">The SARS-CoV S glycoprotein: expression and functional characterization</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chakraborti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Dimitrov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gramatikoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Dimitrov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">312</biblScope>
			<biblScope from="1159" to="1164" unit="page" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title level="m" type="main">Presents the first characterization of the fusogenic function of SARS-CoV</title>
		<imprint />
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Babcock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Esshaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Jr &amp;amp; Ambrosino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope from="4552" to="4560" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody</title>
		<author>
			<persName><forename type="first">P</forename><surname>Prabakaran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope from="15829" to="15836" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">X</forename><surname>Qu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope from="29588" to="29595" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Receptor and viral determinants of SARScoronavirus adaptation to human ACE2</title>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope from="1634" to="1643" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sheahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rockx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Donaldson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Corti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Baric</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope from="8721" to="8732" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">SARS-associated coronavirus</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Holmes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">348</biblScope>
			<biblScope from="1948" to="1951" unit="page" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients</title>
		<author>
			<persName><forename type="first">H</forename><surname>Hofmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope from="6134" to="6142" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Angiotensinconverting enzyme 2: a functional receptor for SARS coronavirus</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kuhn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Choe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Farzan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell. Mol. Life Sci</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope from="2738" to="2743" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">A model of the ACE2 structure and function as a SARS-CoV receptor</title>
		<author>
			<persName><forename type="first">P</forename><surname>Prabakaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Dimitrov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">314</biblScope>
			<biblScope from="235" to="241" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Comput. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope from="254" to="257" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity</title>
		<author>
			<persName><forename type="first">Y</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">344</biblScope>
			<biblScope from="106" to="113" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Jeffers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope from="15748" to="15753" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope from="5642" to="5650" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Specific asparagine-linked glycosylation sites are critical for DC-SIGN-and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lohani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Cho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope from="12029" to="12039" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors</title>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope from="938" to="947" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
	<note>The first published paper to show that peptides derived from the HR2 region of the SARS-CoV S. protein could inhibit SARS-CoV infection</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Structural characterization of the SARS-coronavirus spike S fusion protein core</title>
		<author>
			<persName><forename type="first">B</forename><surname>Tripet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">279</biblScope>
			<biblScope from="20836" to="20849" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">279</biblScope>
			<biblScope from="49414" to="49419" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope from="7217" to="7226" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Keng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope from="3289" to="3296" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bukreyev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope from="2122" to="2127" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">428</biblScope>
			<biblScope from="561" to="564" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice</title>
		<author>
			<persName><forename type="first">H</forename><surname>Bisht</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope from="6641" to="6646" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope from="2678" to="2688" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate Fc&#947;RIIdependent entry into B cells in vitro</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">W</forename><surname>Kam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope from="729" to="740" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design</title>
		<author>
			<persName><forename type="first">Y</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Heck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lustigman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope from="5757" to="5767" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets</title>
		<author>
			<persName><forename type="first">M</forename><surname>Czub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Weingartl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Czub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope from="2273" to="2279" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets</title>
		<author>
			<persName><forename type="first">H</forename><surname>Weingartl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope from="12672" to="12676" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Identification of a receptorbinding domain of the spike glycoprotein of human coronavirus HCoV-229E</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bonavia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Zelus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Wentworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Talbot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Holmes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope from="2530" to="2538" unit="page" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kubo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Taguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope from="5403" to="5410" unit="page" />
			<date type="published" when="1994" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Inactivated SARS-CoV vaccine elicits high titers of spike proteinspecific antibodies that block receptor binding and virus entry</title>
		<author>
			<persName><forename type="first">Y</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Siddiqui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">325</biblScope>
			<biblScope from="445" to="452" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines</title>
		<author>
			<persName><forename type="first">Y</forename><surname>He</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virology</title>
		<imprint>
			<biblScope unit="volume">334</biblScope>
			<biblScope from="74" to="82" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine</title>
		<author>
			<persName><forename type="first">Y</forename><surname>He</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">324</biblScope>
			<biblScope from="773" to="781" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein</title>
		<author>
			<persName><forename type="first">K</forename><surname>Yuan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">319</biblScope>
			<biblScope from="746" to="752" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Amino acid substitutions in the S2 subunit of mouse hepatitis virus variant V51 encode determinants of host range expansion</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Mcroy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Baric</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope from="1414" to="1424" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies</title>
		<author>
			<persName><forename type="first">Y</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Siddiqui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">174</biblScope>
			<biblScope from="4908" to="4915" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<monogr>
		<title level="m" type="main">Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Lai</surname></persName>
		</author>
		<imprint>
			<publisher>SARS-CoV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title />
	</analytic>
	<monogr>
		<title level="j">J. Biomed. Sci</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope from="711" to="727" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Antibodies in the therapy of colon cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Welt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ritter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin. Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope from="683" to="690" unit="page" />
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Nie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Infect. Dis</title>
		<imprint>
			<biblScope unit="volume">190</biblScope>
			<biblScope from="1119" to="1126" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus</title>
		<author>
			<persName><forename type="first">E</forename><surname>Traggiai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Med</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope from="871" to="875" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope from="12123" to="12128" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse</title>
		<author>
			<persName><forename type="first">M</forename><surname>Coughlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virology</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope from="93" to="102" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Structural basis for potent crossneutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge</title>
		<author>
			<persName><forename type="first">B</forename><surname>Rockx</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope from="3220" to="3235" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope from="2536" to="2541" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus</title>
		<author>
			<persName><surname>Van Den</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Brink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope from="1635" to="1644" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Greenough</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Pathol</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope from="455" to="463" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope from="3198" to="3203" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">SARS-CoV, but not HCoV-NL63, utilizes cathepsins to infect cells: viral entry</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv. Exp. Med. Biol</title>
		<imprint>
			<biblScope unit="volume">581</biblScope>
			<biblScope from="335" to="338" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry</title>
		<author>
			<persName><forename type="first">G</forename><surname>Simmons</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope from="11876" to="11881" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Proteolysis of SARS-associated coronavirus spike glycoprotein</title>
		<author>
			<persName><forename type="first">G</forename><surname>Simmons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Rennekamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bates</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv. Exp. Med. Biol</title>
		<imprint>
			<biblScope unit="volume">581</biblScope>
			<biblScope from="235" to="240" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a postendosomal level</title>
		<author>
			<persName><forename type="first">K</forename><surname>Stadler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Respir. Cell Mol. Biol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope from="142" to="149" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Yi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope from="11334" to="11339" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Identification of novel small-molecule inhibitors of severe acute respiratory syndromeassociated coronavirus by chemical genetics</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Y</forename><surname>Kao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chem. Biol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope from="1293" to="1299" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">siRNA targeting the leader sequence of SARS-CoV inhibits virus replication</title>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gene Ther</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope from="751" to="761" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Short interfering RNA confers intracellular antiviral immunity in human cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gitlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Karelsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Andino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">418</biblScope>
			<biblScope from="430" to="434" unit="page" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Inhibition of SARS-CoV replication by siRNA</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antiviral Res</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope from="45" to="48" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S</title>
		<author>
			<persName><forename type="first">S</forename><surname>Akerstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mirazimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Tan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antiviral Res</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope from="219" to="227" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>He</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">580</biblScope>
			<biblScope from="2414" to="2420" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Zheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antivir. Ther</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope from="365" to="374" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Silencing of SARS-CoV spike gene by small interfering RNA in HEK 293T cells</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">L</forename><surname>Qin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">324</biblScope>
			<biblScope from="1186" to="1193" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Silencing SARS-CoV spike protein expression in cultured cells by RNA interference</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">560</biblScope>
			<biblScope from="141" to="146" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope from="944" to="951" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry</title>
		<author>
			<persName><forename type="first">G</forename><surname>Simmons</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope from="4240" to="4245" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection</title>
		<author>
			<persName><forename type="first">S</forename><surname>Matsuyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ujike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Morikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tashiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Taguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope from="12543" to="12547" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">The life cycle of SARS coronavirus in Vero E6 cells</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Qinfen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Virol</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope from="332" to="337" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Pathogenetic mechanisms of severe acute respiratory syndrome</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Korteweg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Mcnutt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virus Res</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope from="4" to="12" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Pathology and pathogenesis of severe acute respiratory syndrome</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Korteweg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Pathol</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope from="1136" to="1147" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Ding</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pathol</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope from="622" to="630" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">SARS coronavirus and innate immunity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Frieman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Baric</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virus Res</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope from="101" to="112" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Navas-Martin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Biol. Rev</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope from="635" to="664" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">SARS coronavirus: a new challenge for prevention and therapy</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Holmes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Invest</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope from="1605" to="1609" unit="page" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">The intracellular sites of early replication and budding of SARS-coronavirus</title>
		<author>
			<persName><forename type="first">S</forename><surname>Stertz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virology</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope from="304" to="315" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Inoue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope from="8722" to="8729" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hakansson-Mcreynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Caffrey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope from="11965" to="11971" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">DNA vaccine of SARS-CoV S gene induces antibody response in mice</title>
		<author>
			<persName><forename type="first">P</forename><surname>Zhao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Biochim. Biophys. Sin. (Shanghai)</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope from="37" to="41" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope from="1906" to="1910" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Priming with SARS-CoV S DNA and boosting with SARS-CoV S epitopes specific for CD4 + and CD8 + T cells promote cellular immune responses</title>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope from="6981" to="6991" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus</title>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope from="4694" to="4700" unit="page" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Obstacles and advances in SARS vaccine development</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Taylor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope from="863" to="871" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">From genome to antivirals: SARS as a test tube</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kliger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">Y</forename><surname>Levanon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gerber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Discov. Today</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope from="345" to="352" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">D</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope from="400" to="406" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ujike</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope from="588" to="592" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope from="797" to="801" unit="page" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice</title>
		<author>
			<persName><forename type="first">K</forename><surname>Subbarao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope from="3572" to="3577" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">A single amino acid substitution in the S1 and S2 spike protein domains determines the neutralization escape phenotype of SARS-CoV</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Mitsuki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Microbes Infect</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope from="908" to="915" unit="page" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ter Meulen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope from="2139" to="2141" unit="page" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Therapy with a severe acute respiratory syndrome-associated coronavirusneutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters</title>
		<author>
			<persName><forename type="first">A</forename><surname>Roberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Infect. Dis</title>
		<imprint>
			<biblScope unit="volume">193</biblScope>
			<biblScope from="685" to="692" unit="page" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>